Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial. (BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2022)